---
title: "ORKA.US (ORKA.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ORKA.US/news.md"
symbol: "ORKA.US"
name: "ORKA.US"
parent: "https://longbridge.com/en/quote/ORKA.US.md"
datetime: "2026-05-19T21:40:48.590Z"
locales:
  - [en](https://longbridge.com/en/quote/ORKA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ORKA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ORKA.US/news.md)
---

# ORKA.US (ORKA.US) — Related News

### [Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock](https://longbridge.com/en/news/286877509.md)
*2026-05-19T08:21:28.000Z*
> Oruka Therapeutics SVP Arjun Agarwal sold 10,290 shares at $59.07 each, totaling $607,830.30, representing a 38.55% decr

### [Barclays Remains a Buy on Oruka Therapeutics (ORKA)](https://longbridge.com/en/news/286389801.md)
*2026-05-14T09:17:59.000Z*
> Barclays analyst Etzer Darout has maintained a Buy rating on Oruka Therapeutics (ORKA) with a price target of $160.00. D

### [Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential](https://longbridge.com/en/news/286323165.md)
*2026-05-13T21:55:19.000Z*
> TD Cowen analyst Tyler Van Buren has maintained a Buy rating on ORKA stock, citing strong clinical data for ORKA-001 in 

### [Oruka Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286309677.md)
*2026-05-13T20:09:35.000Z*
### [Halozyme and Oruka sign agreement for Hypercon technology](https://longbridge.com/en/news/285514846.md)
*2026-05-07T08:07:28.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.

### [](https://longbridge.com/en/news/284944635.md)
*2026-05-01T22:02:13.000Z*
> The Nasdaq Biotechnology Index fell 1.09%. Among its constituents, Summit Therapeutics Plc dropped 24.91%, Syndax Pharma

### [](https://longbridge.com/en/news/284616482.md)
*2026-04-29T16:51:47.000Z*
> Oruka Therapeutics shares are trading lower after the company priced an upsized $700 million public offering of 9.66 mil

### [Oruka Therapeutics Drops 7.9% After Stock Offering](https://longbridge.com/en/news/284614293.md)
*2026-04-29T16:42:17.000Z*
> Oruka Therapeutics (ORKA.US) current price $68.125, down 7.93% for the day, intraday drop below 8%, market capitalizatio